Drug Combinations To Be Tested in ALS

A trial that will test two drug combinations, both of which have shown benefit in mouse models of ALS, will open soon at about 20 centers throughout the United States.

The study coordinators, who are based at the Eleanor and Lou Gehrig MDA/ALS Center at Columbia University in New York, expect to enroll 120 people.

In the first part of the trial, the investigators will test two drug combinations -- minocycline with creatine, and celecoxib (Celebrex) with creatine -- to see which combination (if either) warrants further testing. In the next phase, the winning combination will move to a large-scale trial.

For more information, contact Carolyn Doorish in New York at cd2141@columbia.edu or (212) 305-2027.